anti muc21 antibody  (Novus Biologicals)

Journal: Frontiers in Oncology

Article Title: MUC21 is downregulated in oral squamous cell carcinoma and associated with poor prognosis

doi: 10.3389/fonc.2026.1767261

Figure Lengend Snippet: MUC21 Expression by analyzing high-throughput dataset including Affymetrix GeneChip ® Human Transcriptome Array 2.0(HTA), GSE34105 from GEO and TCGA RNAseq data. (A-F) , the heatmaps of hierarchical clustering and volcano plots of differential gene expressions revealed by HTA based on 10 paired OSCC and adjacent normal oral tissue; GSE34105 based on 62 OSCC and 16 normal oral tissue; TCGA base on 266 OSCC and 19 normal oral tissue. Genes with a fold change >2 and adj-P-value of <0.05 were highlighted. (G, H) the up and down regulated genes in the three datasets were intersected and it was showed that 73 was up and 102 were down regulated in the intersection which comprised only MUC15 and MUC21 from Mucin family. (I) relative expression level (the median of the three datasets) comparison showed that MUC21 was more down regulated than MUC15, the chart was created from Excel (Microsoft ® for Excel). OSCC, oral squamous cell carcinoma.

Article Snippet: Following antigen retrieval, sections were blocked with 10% normal serum and then incubated with either anti-MUC21 antibody (NBP2-31023; Polyclonal; 1:200; NOVUS Biologicals, Littleton, CO, USA), anti-KRT4 antibody (CY5773, monoclonal; 1:200; Abways Technology, Shanghai, China), anti-KRT13 antibody (CY5744, monoclonal; 1:100; Abways Technology, Shanghai, China) or anti-CRNN antibody (TA811824S, monoclonal; 1:500; OriGene Technologies Inc, Rockville, MD, US)for 2 hours at 37°C.

Techniques: Expressing, High Throughput Screening Assay, RNA sequencing, Comparison

Journal: Frontiers in Oncology

Article Title: MUC21 is downregulated in oral squamous cell carcinoma and associated with poor prognosis

doi: 10.3389/fonc.2026.1767261

Figure Lengend Snippet: MUC21 co expression gene analysis by cor.test of R language in the TCGA. (A-K) , the correlation analysis of MUC21 to SPRR3, MAL, TMPRSS11B, CAPN14, FUT6, CEACAM7, CRNN, DYNAP, IL36A, KRT13, KRT4. R value was set at more than 0.7, and P value was set less than 0.001. (L) , Top five negatively or positively correlated genes were showed in circos map.

Article Snippet: Following antigen retrieval, sections were blocked with 10% normal serum and then incubated with either anti-MUC21 antibody (NBP2-31023; Polyclonal; 1:200; NOVUS Biologicals, Littleton, CO, USA), anti-KRT4 antibody (CY5773, monoclonal; 1:200; Abways Technology, Shanghai, China), anti-KRT13 antibody (CY5744, monoclonal; 1:100; Abways Technology, Shanghai, China) or anti-CRNN antibody (TA811824S, monoclonal; 1:500; OriGene Technologies Inc, Rockville, MD, US)for 2 hours at 37°C.

Techniques: Expressing

Journal: Frontiers in Oncology

Article Title: MUC21 is downregulated in oral squamous cell carcinoma and associated with poor prognosis

doi: 10.3389/fonc.2026.1767261

Figure Lengend Snippet: Quantitative qRT-PCR and immunohistochemistry analysis of MUC21, KRT4, KRT13, and CRNN in OSCC and para-OSCC. (A-D) showed that MUC21, KRT4, KRT13 and CRNN were down regulated in OSCC than para-OSCC (P< 0.0001), the expression levels were normalized against GAPDH. (E) Spearman correlation analysis showed that MUC21was related with KRT4, KRT13 and CRNN at mRNA level. (F-I) showed that MUC21 and KRT4 were down regulated in OSCC than para-OSCC (P<0.0001); KRT13 was down regulated in OSCC than para-OSCC (P <0.05); and CRNN was also down regulated in OSCC than para-OSCC (P<0.001). (J) Spearman correlation analysis showed that MUC21 was related with KRT4, KRT13 and CRNN at protein level too.

Article Snippet: Following antigen retrieval, sections were blocked with 10% normal serum and then incubated with either anti-MUC21 antibody (NBP2-31023; Polyclonal; 1:200; NOVUS Biologicals, Littleton, CO, USA), anti-KRT4 antibody (CY5773, monoclonal; 1:200; Abways Technology, Shanghai, China), anti-KRT13 antibody (CY5744, monoclonal; 1:100; Abways Technology, Shanghai, China) or anti-CRNN antibody (TA811824S, monoclonal; 1:500; OriGene Technologies Inc, Rockville, MD, US)for 2 hours at 37°C.

Techniques: Quantitative RT-PCR, Immunohistochemistry, Expressing

Journal: Frontiers in Oncology

Article Title: MUC21 is downregulated in oral squamous cell carcinoma and associated with poor prognosis

doi: 10.3389/fonc.2026.1767261

Figure Lengend Snippet: MUC21 expression analysis in OSCC and para-OSCC via immunohistochemistry (IHC) and its relation with critical clinical characters. (A) a whole block of OSCC and para-OSCC tissue analyzed by IHC showed that MUC21 was expressed in para-OSCC epithelium and lost in OSCC. (B) MUC21 expression between OSCC and para-OSCC in 102 paired patient samples was quantified by mean optical density (MOD) values. MUC21 decreased significantly in OSCC (P < 0.0001). Box plots represent the median, 25th, and 75th percentiles of the data. (C–H) displayed matched para-OSCC and OSCC. (D, F, H) represented well, moderate, and poor differentiation of OSCC, respectively. Unannotated Scale bar = 100 μm. The Scale bar of the block tissue was 1mm. (I) decreased MUC21 expression level was related with cervical lymphatic metastasis and OSCC differentiation. “pN0” means no lymphatic metastasis, “pN1-PN3” referred to different degrees of lymphatic metastasis; “well +moderate” and “poor” referred to different degrees of differentiation.

Article Snippet: Following antigen retrieval, sections were blocked with 10% normal serum and then incubated with either anti-MUC21 antibody (NBP2-31023; Polyclonal; 1:200; NOVUS Biologicals, Littleton, CO, USA), anti-KRT4 antibody (CY5773, monoclonal; 1:200; Abways Technology, Shanghai, China), anti-KRT13 antibody (CY5744, monoclonal; 1:100; Abways Technology, Shanghai, China) or anti-CRNN antibody (TA811824S, monoclonal; 1:500; OriGene Technologies Inc, Rockville, MD, US)for 2 hours at 37°C.

Techniques: Expressing, Immunohistochemistry, Blocking Assay

Journal: Frontiers in Oncology

Article Title: MUC21 is downregulated in oral squamous cell carcinoma and associated with poor prognosis

doi: 10.3389/fonc.2026.1767261

Figure Lengend Snippet: Kaplan–Meier survival analyses for postoperative OSCC patients based on MUC21 expression. (A, B) Overall Survival (OS) and disease-free survival (DFS)with low MUC21 expression were significantly shorter than those with high MUC21 expression (P = 0.012 for OS, P<0.0001 for DFS). (C, D) , Forest map: The univariate analysis of OS and DFS in OSCC patients. (E, F) , Forest map: The multivariate analysis of OS and DFS in OSCC patients.

Article Snippet: Following antigen retrieval, sections were blocked with 10% normal serum and then incubated with either anti-MUC21 antibody (NBP2-31023; Polyclonal; 1:200; NOVUS Biologicals, Littleton, CO, USA), anti-KRT4 antibody (CY5773, monoclonal; 1:200; Abways Technology, Shanghai, China), anti-KRT13 antibody (CY5744, monoclonal; 1:100; Abways Technology, Shanghai, China) or anti-CRNN antibody (TA811824S, monoclonal; 1:500; OriGene Technologies Inc, Rockville, MD, US)for 2 hours at 37°C.

Techniques: Expressing

Journal: Frontiers in Oncology

Article Title: MUC21 is downregulated in oral squamous cell carcinoma and associated with poor prognosis

doi: 10.3389/fonc.2026.1767261

Figure Lengend Snippet: In vitro cell lines experiment post overexpression and knockdown of MUC21. (A) MUC21 was significantly overexpressed and knocked down in CAL27 and HN6. (B) CCK-8 assay on CAL27 and HN6 post MUC21 manipulation. (C) Transwell assay without Matrigel coated filter of CAL27 and HN6 post MUC21 manipulation. (D) Transwell assay with Matrigel coated filter of CAL27 and HN6 post MUC21 manipulation. (E) wound-healing assay conducted at 24 hours post MUC21 manipulation in CAL27 and HN6 cells. NC: negative control, SH: MUC21 knockdown, OE: MUC21 overexpression. Statistical significance is denoted by *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

Article Snippet: Following antigen retrieval, sections were blocked with 10% normal serum and then incubated with either anti-MUC21 antibody (NBP2-31023; Polyclonal; 1:200; NOVUS Biologicals, Littleton, CO, USA), anti-KRT4 antibody (CY5773, monoclonal; 1:200; Abways Technology, Shanghai, China), anti-KRT13 antibody (CY5744, monoclonal; 1:100; Abways Technology, Shanghai, China) or anti-CRNN antibody (TA811824S, monoclonal; 1:500; OriGene Technologies Inc, Rockville, MD, US)for 2 hours at 37°C.

Techniques: In Vitro, Over Expression, Knockdown, CCK-8 Assay, Transwell Assay, Wound Healing Assay, Negative Control

Journal: Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology

Article Title: Searching for new early detection markers of OED and oral SCC using oral liquid-based cytology

doi: 10.1016/j.ajoms.2023.11.007

Figure Lengend Snippet: Fig. 1. Papanicolaou staining in liquid-based cytology (LBC) samples and BRD4, c-MYC, TP53, and MUC21 immunohistochemical study in oral cytological samples: (A) NILM, (B) LSIL, (C) HSIL, and (D) SCC. (E-H) BRD4 immunocytochemical staining. Although BRD4 staining was generally negative in (E) NILM samples, (F) positive nuclear staining was observed in LSIL, (G) HSIL, and (H) SCC samples. (I-L) c-MYC immunocytochemical staining. Although c-MYC staining was generally negative in (I) NILM samples, positive nuclear staining was observed in (J) LSIL, (K) HSIL, and (L) SCC samples. (M-P) TP53 immunocytochemical staining. Although TP53 staining was generally negative in (M) NILM, (N) LSIL, and (O) HSIL samples, positive nuclear staining was observed in (P) SCC samples. (Q-T) MUC21 immunocytochemical staining. Although MUC21 staining was generally positive in (M) NILM and (N) LSIL, negative cytoplasmic staining was observed in (O) HSIL and (T) SCC samples. Original magnification, 400 x. Scale bars, 20 µm. NILM, negative for intraepithelial lesion or malignancy; LSIL, low‑grade squamous intra epithelial lesion; HSIL, high‑grade squamous intraepithelial lesion; SCC, squamous cell carcinoma.

Article Snippet: All slides were subjected to antigen retrieval using 10 mM Tris-HCl, 1 mM EDTA-2Na (pH8.0) in a microwave oven of 1000 W for 20 min, followed by incubation with a rabbit polyclonal anti-TP53 antibody (1:50 dilution; clone ab131442; Abcam, Cambridge, MA, USA), a rabbit monoclonal anti-cMYC antibody (1:100 dilution; clone ab32072; Abcam), a rabbit polyclonal anti-MUC21 antibody (1:200 dilution; clone NBP2–31023; Novus), or a rabbit monoclonal anti-BRD4 antibody (1:100 dilution; clone ab128874; Abcam).

Techniques: Staining, Immunohistochemical staining

Journal: Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology

Article Title: Searching for new early detection markers of OED and oral SCC using oral liquid-based cytology

doi: 10.1016/j.ajoms.2023.11.007

Figure Lengend Snippet: Fig. 2. Histopathological and immunohistochemical expressions patterns of BRD4, c‑MYC, TP53, and MUC21 in normal epithelium (NOE), hyperplasia (HYP), oral epithelial dysplasia (OED), and squamous cell carcinoma (SCC) samples. (A, E, I, M, Q) NOE, (B, F, J, N, R) HYP, (C, G, K, O, S) OED and (D, H, L, P, T) SCC. (A-D) Hematoxylin and eosin (H&E), (E-H) BRD4, (I-L) c-MYC, (M-P) TP53, and (Q-T) MUC21. Original magnification, 100x. Scale bars, 100 µm.

Article Snippet: All slides were subjected to antigen retrieval using 10 mM Tris-HCl, 1 mM EDTA-2Na (pH8.0) in a microwave oven of 1000 W for 20 min, followed by incubation with a rabbit polyclonal anti-TP53 antibody (1:50 dilution; clone ab131442; Abcam, Cambridge, MA, USA), a rabbit monoclonal anti-cMYC antibody (1:100 dilution; clone ab32072; Abcam), a rabbit polyclonal anti-MUC21 antibody (1:200 dilution; clone NBP2–31023; Novus), or a rabbit monoclonal anti-BRD4 antibody (1:100 dilution; clone ab128874; Abcam).

Techniques: Immunohistochemical staining

Journal: Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology

Article Title: Searching for new early detection markers of OED and oral SCC using oral liquid-based cytology

doi: 10.1016/j.ajoms.2023.11.007

Figure Lengend Snippet: Fig. 4. The correlation between the labeling index and the relative mRNA levels of each marker (BRD4, c-MYC, TP53, and MUC21) in the oral cytological specimens. These markers displayed significant positive correlations: (A) BRD4 (R= 0.781, p < 0.01), (B) c‑MYC (R=0.807, p < 0.01), (C) TP53 (R=0.606, p < 0.01), and (D) MUC21 (R=0.514, p < 0.05).

Article Snippet: All slides were subjected to antigen retrieval using 10 mM Tris-HCl, 1 mM EDTA-2Na (pH8.0) in a microwave oven of 1000 W for 20 min, followed by incubation with a rabbit polyclonal anti-TP53 antibody (1:50 dilution; clone ab131442; Abcam, Cambridge, MA, USA), a rabbit monoclonal anti-cMYC antibody (1:100 dilution; clone ab32072; Abcam), a rabbit polyclonal anti-MUC21 antibody (1:200 dilution; clone NBP2–31023; Novus), or a rabbit monoclonal anti-BRD4 antibody (1:100 dilution; clone ab128874; Abcam).

Techniques: Labeling, Marker

Journal: Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology

Article Title: Searching for new early detection markers of OED and oral SCC using oral liquid-based cytology

doi: 10.1016/j.ajoms.2023.11.007

Figure Lengend Snippet: Fig. 5. Receiver operating characteristic analysis for LSIL or higher category specimens were screened using BRD4 (red line), c-MYC (green line), MUC21 (brown line), and TP53 (blue line) as candidate markers. The optimal cut-off values of each markers were calculated using ‘closest-topleft’ (10, 28).

Article Snippet: All slides were subjected to antigen retrieval using 10 mM Tris-HCl, 1 mM EDTA-2Na (pH8.0) in a microwave oven of 1000 W for 20 min, followed by incubation with a rabbit polyclonal anti-TP53 antibody (1:50 dilution; clone ab131442; Abcam, Cambridge, MA, USA), a rabbit monoclonal anti-cMYC antibody (1:100 dilution; clone ab32072; Abcam), a rabbit polyclonal anti-MUC21 antibody (1:200 dilution; clone NBP2–31023; Novus), or a rabbit monoclonal anti-BRD4 antibody (1:100 dilution; clone ab128874; Abcam).

Techniques: